Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed: 20,548
Companies: 1,769
Drugs tracked: 4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources

Quick answer

Cisplatin

DEXTROMETHORPHANE ELERTE 1,5 mg/ml, sirop, AZD3470, AZD3470, Midazolam-ratiopharm® 2 mg/ml orale Lösung

Drug-AZD8931

First-in-Human trial of DS9051b in participants with advanced solid tumors

First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)

JNJ-56021927

Koselugo 25 mg hard capsules, Koselugo 10 mg hard capsules

LENVIMA 4 mg hard capsules, volrustomig, Kisplyx 10 mg hard capsules, Kisplyx 4 mg hard capsules, LENVIMA 10 mg hard capsules

Locametz 25 micrograms kit for radiopharmaceutical preparation, -, Pluvicto 1 000 MBq/mL solution for injection/infusion

Lynparza 100 mg film-coated tablets, AZD2281, AZD2281, AZD2281

MYCOPHENOLATE MOFETIL, INFLIXIMAB, Rilvegostomig, Rilvegostomig, volrustomig, CARBOPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., Datopotamab deruxtecan, AZD7789

Mevrometostat Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

NKTR-214 (Cohort A)

PET study of changes in [11C]AZ14132516 uptake following administration of multiple AZD7798 doses to patients with Crohn’s disease.

Phase 1 Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Study of AZD9833 Alone or in Combination in Women with Advanced Breast Cancer

Phase 1 trial of valemetostat and darolutamide in mCRPC

Phase Ib Randomised, Placebo-controlled, Double-blind, Multicentre Study to Assess the Effects and Safety of AZD5462 on top of Dapagliflozin in Participants with Heart Failure and Moderate Renal Impairment

Pluvicto 1 000 MBq/mL solution for injection/infusion, Lutetium (177Lu) rhPSMA-10.1 injection

Sodium Zirconium Cyclosilicate (ZS)

TVB-2640

[225Ac]Ac-AKY-2519 (therapeutic)

Frequently asked questions